Stockscreener 앱 받기
108.16
1.61%
-1.575
Guardant Health Inc 주식(GH)의 최신 뉴스
Merger Talk: What are the future prospects of Guardant Health IncWeekly Loss Report & Daily Profit Maximizing Tips - baoquankhu1.vn
Risk Analysis: Does Tripadvisor Inc have declining or rising EPSJuly 2025 Reactions & Precise Buy Zone Tips - baoquankhu1.vn
Guardant Health Inc (GH) Shares Down 3.74% on Jan 28 - GuruFocus
Is There An Opportunity With Guardant Health, Inc.'s (NASDAQ:GH) 23% Undervaluation? - 富途牛牛
Analysts Are Bullish on These Healthcare Stocks: Guardant Health (GH), Regeneron (REGN) - The Globe and Mail
Guggenheim Raises Price Target on Guardant Health (GH) to $135 | GH Stock News - GuruFocus
Guardant Health: Look For Explosive Revenue Growth Ahead (NASDAQ:GH) - Seeking Alpha
Y Intercept Hong Kong Ltd Has $4.77 Million Holdings in Guardant Health, Inc. $GH - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Vaxcyte (PCVX), Guardant Health (GH) - The Globe and Mail
Universal Beteiligungs und Servicegesellschaft mbH Acquires 106,263 Shares of Guardant Health, Inc. $GH - MarketBeat
Baillie Gifford & Co. Increases Position in Guardant Health, Inc. $GH - MarketBeat
Guardant Health (GH): Court Decision Offers Incremental Positive in Litigation - GuruFocus
Leerink Partners Maintains Guardant Health(GH.US) With Buy Rating - 富途资讯
Guardant Can Try Again To Nix Patent Tied To $83M Verdict - Law360
Wall Street Has a Positive Opinion on Guardant Health (GH) - Finviz
Guardant Health, Inc. $GH is Emerald Mutual Fund Advisers Trust's 8th Largest Position - MarketBeat
Insider Sell: Terilyn Monroe Sells 8,571 Shares of Guardant Heal - GuruFocus
Guardant Health CPO Monroe sells $977k in stock By Investing.com - Investing.com UK
Guardant Health (NASDAQ:GH) Insider Sells $977,865.39 in Stock - MarketBeat
Guardant Health CPO Monroe sells $977k in stock - Investing.com
Avoiding Lag: Real-Time Signals in (GH) Movement - Stock Traders Daily
AI Diagnostics Co.'s Patent Claims Don't Pass Alice Test - Law360
FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal Cancer - Benzinga
Analysts turn more bullish on Guardant Health, Inc. (GH) as 2026 growth catalysts build - MSN
Guardant Health, Inc. Receives FDA Approval for Guardant360®? CDx as Companion Diagnostic for BRAFTOVI®? (Encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer - marketscreener.com
FDA Approves Guardant Health's (GH) Diagnostic for Colorectal Ca - GuruFocus
FDA Approval Boosts Guardant Health (GH) with New Diagnostic Use - GuruFocus
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer - Yahoo Finance
Guardant Health, Inc. $GH Shares Bought by Emerald Advisers LLC - MarketBeat
Guardant Health (NASDAQ:GH) Hits New 12-Month HighHere's Why - MarketBeat
Is Merck’s Guardant Liquid Biopsy Alliance Reshaping the Investment Case for MRK? - Yahoo Finance
Strong Results and Improved Guidance Lifted Guardant Health (GH) in Q4 - Insider Monkey
Inspire Advisors LLC Makes New Investment in Guardant Health, Inc. $GH - MarketBeat
Guardant Health, Inc. (NASDAQ:GH) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Analysts Turn More Bullish on Guardant Health, Inc. (GH) as 2026 Growth Catalysts Build - Insider Monkey
Guardant Health’s Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families in North Carolina - New Bern Live
Guardant Health (GH) Joins Forces with Merck for Oncology Advancements - GuruFocus
Guardant Health announces multi-year strategic collaboration agreement with Merck for companion diagnostics - BioSpectrum Asia
Guardant Health Announces Multi-Year Strategic Collaboration Agreement With Merck - TradingView — Track All Markets
Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform - Chartmill
Campbell & CO Investment Adviser LLC Makes New $1.19 Million Investment in Guardant Health, Inc. $GH - MarketBeat
Guardant Health, Inc. (GH) Stock Analysis: Unlocking Potential in Precision Oncology with a Robust Revenue Growth - DirectorsTalk Interviews
Guardant Health: Shield Colorectal Cancer Screening To Sustain Growth - Seeking Alpha
Guardant Health stock hits 52-week high at 113.98 USD By Investing.com - Investing.com Nigeria
IPO Launch: How does Guardant Health Inc compare to its peersJuly 2025 Reactions & Daily Profit Maximizing Tips - baoquankhu1.vn
Guardant Health stock hits 52-week high at 113.98 USD - Investing.com India
Sumitomo Mitsui Trust Group Inc. Has $47.12 Million Position in Guardant Health, Inc. $GH - MarketBeat
Global Pan-Genomic and Multi-Gene Panel Testing Market Forecast to Hit US$ 25.91 Billion by 2032 at 12.04% CAGR, Driven by Growing Demand for Comprehensive Multi-Gene Diagnostics: AnalystView Market Insights - GlobeNewswire Inc.
BLOODPAC Publishes New Standards for Liquid Biopsy Tests That Monitor for Cancer Recurrence - PA Media
Guardant Health (NASDAQ:GH): Strongest Q3 Results from the Testing & Diagnostics Services Group - Yahoo Finance
Guardant Health Announces Strong 2025 Preliminary Revenue Growth - The Globe and Mail
Guardant Health guides Q4 and FY25 revenue above consensus - MSN
Guardant Health (NASDAQ:GH) Reaches New 12-Month HighStill a Buy? - MarketBeat
Guardant Health shares up 2.4% after preliminary Q4 revenue beats estimates - marketscreener.com
Guardant Health, Inc. (GH) Stock Analysis: Strong Buy Potential with 38.5% Revenue Growth and Robust Analyst Support - DirectorsTalk Interviews
Guardant Health rises after Q4 revenue surpasses estimate - TradingView — Track All Markets
Guardant Health, Inc. $GH Shares Sold by D.A. Davidson & CO. - MarketBeat
Guardant Health Sees 39% Rise in Q4 Preliminary Revenue - marketscreener.com
0.10%
2.27%
자본화:
|
볼륨(24시간):